ResMed Announces Study Results On SleepMinder Device

(RTTNews) - ResMed (RMD) announced results from a study presented at the ESC Congress 2014 in Barcelona, Spain, looking at the use of the at-home, contactless, bedside SleepMinder device to diagnose sleep-disordered breathing or SDB, the most common co-morbidity in patients with heart failure or HF.

The company stated that the study highlighted bedside device could reduce misdiagnosis of sleep-disordered breathing common heart failure co-morbidity, support optimal treatment and reduce need for inpatient care.

The study also assessed how SleepMinder, when used over two weeks, compared to a current gold-standard of diagnosis, a single night assessment via inpatient polysomnography or PSG.

The investigating team reported that, after using SleepMinder for two weeks, 57% of patients were consistently above a threshold that would require treatment for their SDB (AHI=15). This rose to 74% in patients who were followed up for 12 months.

SDB is the most common co-morbidity in HF, affecting between 50-75% of the 15 million HF patients in Europe.